explore -WSS

explore

author：entertainment 2025-10-01 15:28:25 - browse：52236

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

Wikipedia

WSS

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

Pope Francis asks Church to identify 21st

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

Trump surgeon general acknowledges mistakes during Covid

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

AstraZeneca chief proposes a novel edit to the drug pricing bill

Wikipedia

explore

explore

Moonlake's readout produced a cash windfall. Risks remain

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

In Memoriam: Notable people who died in 2023

Israel withdraws forces after 2

Medicare proposal to cover medical devices draws a mixed reaction

Condition critical? Britain's beloved but battered National Health Service turns 75

Supreme Court strikes down use of affirmative action

ALS advocates say criticism of new drugs misses bigger picture

State Dept. review finds Biden bears some blame for Afghanistan failures

How to fix cancer clinical trials' diversity problem

hotspot

What American doctors can learn from their Israeli counterparts

The leaders of Italy and Poland say European Union should focus on stopping migration

Condition critical? Britain's beloved but battered National Health Service turns 75

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Illumina names Agilent executive as new CEO

Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder

knowledge

leisure time

Wikipedia

focus